Technical Analysis for APRE - Aprea Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Weak + Overbought | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -1.53% | |
| Bollinger Band Squeeze | Range Contraction | -1.53% | |
| Earnings Movers | Other | -1.53% | |
| Weak + Overbought | Other | -1.53% | |
| BB Squeeze + Upper Band Touch | Range Contraction | -1.53% |
| Alert | Time |
|---|---|
| Down 5% | about 14 hours ago |
| Possible Inside Day | about 14 hours ago |
| Down 3% | about 18 hours ago |
| Down 2 % | about 18 hours ago |
| Down 1% | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.78 |
| Average Volume | 35,125 |
| 200-Day Moving Average | 4.95 |
| 50-Day Moving Average | 5.94 |
| 20-Day Moving Average | 5.37 |
| 10-Day Moving Average | 5.47 |
| Average True Range | 0.36 |
| RSI (14) | 54.55 |
| ADX | 23.62 |
| +DI | 18.76 |
| -DI | 15.59 |
| Chandelier Exit (Long, 3 ATRs) | 4.89 |
| Chandelier Exit (Short, 3 ATRs) | 5.99 |
| Upper Bollinger Bands | 5.82 |
| Lower Bollinger Band | 4.91 |
| Percent B (%b) | 0.97 |
| BandWidth | 17.01 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.17 |
| MACD Histogram | 0.1063 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.27 | ||||
| Resistance 3 (R3) | 6.25 | 6.06 | 6.19 | ||
| Resistance 2 (R2) | 6.06 | 5.94 | 6.07 | 6.17 | |
| Resistance 1 (R1) | 5.93 | 5.87 | 5.84 | 5.96 | 6.14 |
| Pivot Point | 5.75 | 5.75 | 5.70 | 5.76 | 5.75 |
| Support 1 (S1) | 5.62 | 5.62 | 5.52 | 5.64 | 5.46 |
| Support 2 (S2) | 5.43 | 5.55 | 5.44 | 5.43 | |
| Support 3 (S3) | 5.30 | 5.43 | 5.41 | ||
| Support 4 (S4) | 5.33 |
